{"id":"tjo-083","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL3137322","moleculeType":"Small molecule","molecularWeight":"146.14"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TJO-083 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin, which are used to treat type 2 diabetes.","oneSentence":"TJO-083 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06427031","phase":"PHASE3","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2023-07-14","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":271},{"nctId":"NCT05346783","phase":"PHASE1, PHASE2","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2021-10-14","conditions":"Dry Eye Syndromes","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TJO-083","genericName":"TJO-083","companyName":"Taejoon Pharmaceutical Co., Ltd.","companyId":"taejoon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TJO-083 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}